Professor Daniel Murphy
- Professor of Lung Cancer & Mesothelioma (Therapeutic Science Research)
telephone:
01413308710
email:
Daniel.Murphy@glasgow.ac.uk
Institute of Cancer Sciences, CRUK Beatson Institute, Garscube Estate, Bearsden, G61 1BD
https://orcid.org/0000-0002-5538-5468Research interests
Research groups
- Cancer Hallmarks to Novel Therapies
- Cancer Evolution in Time & Space
- Immunology & Cancer
Publications
2024
Vringer, E. et al. (2024) Mitochondrial outer membrane integrity regulates a ubiquitin-dependent and NF-κB-mediated inflammatory response. EMBO Journal, 43(6), pp. 904-930. (doi: 10.1038/s44318-024-00044-1) (PMID:38337057) (PMCID:PMC10943237)
Skalka, G. L., Tsakovska, M. and Murphy, D. (2024) Kinase signaling adaptation supports dysfunctional mitochondria in disease. Frontiers in Molecular Biosciences, 11, 1354682. (doi: 10.3389/fmolb.2024.1354682)
2023
Whyte, D. et al. (2023) NUAK1 governs centrosome replication in pancreatic cancer via MYPT1/PP1β and GSK3β-dependent regulation of PLK4. Molecular Oncology, 17(7), pp. 1212-1227. (doi: 10.1002/1878-0261.13425) (PMID:36975767) (PMCID:PMC10323901)
Farahmand, P. et al. (2023) Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma. Frontiers in Toxicology, 5, 1200650. (doi: 10.3389/ftox.2023.1200650) (PMID:37441092) (PMCID:PMC10333928)
Vitale, I. et al. (2023) Apoptotic cell death in disease—current understanding of the NCCD 2023. Cell Death and Differentiation, 30(5), pp. 1097-1154. (doi: 10.1038/s41418-023-01153-w) (PMID:37100955) (PMCID:PMC10130819)
Villar, V. H. et al. (2023) Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer. Nature Chemical Biology, 19(3), pp. 292-300. (doi: 10.1038/s41589-022-01154-9) (PMID:36280791) (PMCID:PMC9974483)
2022
Yanchus, C. et al. (2022) A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation. Science, 378(6615), pp. 68-78. (doi: 10.1126/science.abj2890) (PMID:36201590) (PMCID:PMC9926876)
Müller, M. et al. (2022) Human-correlated genetic HCC models identify combination therapy for precision medicine [Pre-print]. Research Square, (doi: 10.21203/rs.3.rs-1638504/v1)
Blomme, A. et al. (2022) THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Molecular Medicine, 14(3), e14764. (doi: 10.15252/emmm.202114764) (PMID:35014179) (PMCID:PMC8899912)
2021
Marini, A. et al. (2021) The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nature Communications, 12, 4920. (doi: 10.1038/s41467-021-25173-7) (PMID:34389715) (PMCID:PMC8363647)
Yun, S. et al. (2021) TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discovery, 2(2), pp. 162-185. (doi: 10.1158/2643-3230.bcd-20-0029) (PMID:33860275) (PMCID:PMC8043621)
2020
Rodrigues, F. S., Miranda, V. S., Carneiro-Lobo, T. C., Scalabrini, L. C., Kruspig, B., Levantini, E., Murphy, D. J. and Bassères, D. S. (2020) IKKβ kinase promotes stemness, migration, and invasion in KRAS-driven lung adenocarcinoma cells. International Journal of Molecular Sciences, 21(16), 5806. (doi: 10.3390/ijms21165806) (PMID:32823550) (PMCID:PMC7460870)
Muthalagu, N. et al. (2020) Repression of the type I interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in pancreatic ductal adenocarcinoma. Cancer Discovery, 10(6), pp. 872-887. (doi: 10.1158/2159-8290.CD-19-0620) (PMID:32200350) (PMCID:PMC7611248)
2019
Bott, A. J. et al. (2019) Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism. Cell Reports, 29(5), 1287-1298.e6. (doi: 10.1016/j.celrep.2019.09.056) (PMID:31665640) (PMCID:PMC6886125)
Neidler, S. et al. (2019) Identification of a clinically relevant signature for early progression in KRAS-driven lung adenocarcinoma. Cancers, 11(5), 600. (doi: 10.3390/cancers11050600) (PMID:31032816) (PMCID:PMC6562816)
Scopelliti, A., Bauer, C. , Yu, Y., Zhang, T., Kruspig, B., Murphy, D. J. , Vidal, M., Maddocks, O. D.K. and Cordero, J. B. (2019) A neuronal relay mediates a nutrient responsive gut/fat body axis regulating energy homeostasis in adult Drosophila. Cell Metabolism, 29(2), 269-284.e10. (doi: 10.1016/j.cmet.2018.09.021) (PMID:30344016) (PMCID:PMC6370946)
2018
Muthalagu, N. and Murphy, D. J. (2018) Is oxidative stress MYC’s Achilles heel? Cell Death and Differentiation, 25(7), pp. 1189-1190. (doi: 10.1038/s41418-018-0117-4) (PMID:29844569) (PMCID:PMC6030217)
Kruspig, B. et al. (2018) The ERBB network facilitates KRAS-driven lung tumorigenesis. Science Translational Medicine, 10(446), eaao2565. (doi: 10.1126/scitranslmed.aao2565) (PMID:29925636) (PMCID:PMC6881183)
Port, J. et al. (2018) Colorectal tumors require NUAK1 for protection from oxidative stress. Cancer Discovery, 8(5), pp. 632-647. (doi: 10.1158/2159-8290.CD-17-0533) (PMID:29500295) (PMCID:PMC5935231)
Monteverde, T., Tait-Mulder, J., Hedley, A.,, Knight, J.R., Sansom, O.J. and Murphy, D.J. (2018) Calcium signalling links MYC to NUAK1. Oncogene, 37(8), pp. 982-992. (doi: 10.1038/onc.2017.394) (PMID:29106388)
Blyth, K. G. and Murphy, D. J. (2018) Progress and challenges in Mesothelioma: from bench to bedside. Respiratory Medicine, 134, pp. 31-41. (doi: 10.1016/j.rmed.2017.11.015)
2017
Walton, J. B. et al. (2017) CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Scientific Reports, 7, 16827. (doi: 10.1038/s41598-017-17119-1) (PMID:29203787) (PMCID:PMC5715106)
Farrell, A. S. et al. (2017) MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nature Communications, 8, 1728. (doi: 10.1038/s41467-017-01967-6) (PMID:29170413) (PMCID:PMC5701042)
Port, J. and Murphy, D. J. (2017) Mesothelioma: identical routes to malignancy from asbestos and carbon nanotubes. Current Biology, 27(21), R1173-R1176. (doi: 10.1016/j.cub.2017.07.026) (PMID:29112873)
Murphy, D. J. and Blyth, K. G. (2017) Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'. Cell Death and Differentiation, 24(9), pp. 1473-1474. (doi: 10.1038/cdd.2017.97) (PMID:28622291)
Hock, A. K. et al. (2017) Development of an inducible mouse model of iRFP713 to track recombinase activity and tumour development in vivo. Scientific Reports, 7, 1837. (doi: 10.1038/s41598-017-01741-0) (PMID:28500323) (PMCID:PMC5431786)
Sarosiek, K. A. et al. (2017) Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific sensitivity to cancer therapeutics. Cancer Cell, 31(1), pp. 142-156. (doi: 10.1016/j.ccell.2016.11.011) (PMID:28017613) (PMCID:PMC5363285)
Iltzsche, F. et al. (2017) An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma. Oncogene, 36(1), pp. 110-121. (doi: 10.1038/onc.2016.181) (PMID:27212033)
2015
Bott, A. J. et al. (2015) Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metabolism, 22(6), pp. 1068-1077. (doi: 10.1016/j.cmet.2015.09.025) (PMID:26603296) (PMCID:PMC4670565)
Monteverde, T., Muthalagu, N., Port, J. and Murphy, D. (2015) Evidence of cancer-promoting roles for AMPK and related kinases. FEBS Journal, 282(24), pp. 4658-4671. (doi: 10.1111/febs.13534) (PMID:26426570)
Neidler, S. and Murphy, D. J. (2015) Studying lung cancer progression: insights from genetically engineered mouse models of cancer. Lung Cancer Management, 4(4), pp. 155-157. (doi: 10.2217/lmt.15.18)
Ichim, G. et al. (2015) Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Molecular Cell, 57(5), pp. 860-872. (doi: 10.1016/j.molcel.2015.01.018) (PMID:25702873) (PMCID:PMC4352766)
Leikam, C. et al. (2015) In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells. Cell Death and Disease, 6(4), e1711. (doi: 10.1038/cddis.2015.71) (PMID:25837487)
Murphy, D. J. and Muthalagu, N. (2015) BIM's up first. Molecular and Cellular Oncology, 2(2), e975083. (doi: 10.4161/23723556.2014.975083)
2014
Kamphorst, J. J. and Murphy, D. J. (2014) The 2014 Beatson International Cancer Conference: Powering the Cancer Machine. Cancer and Metabolism, 2(1), 25. (doi: 10.1186/2049-3002-2-25)
Muthalagu, N., Junttila, M. R., Wiese, K. E., Wolf, E., Morton, J. , Bauer, B., Evan, G. I., Eilers, M. and Murphy, D. J. (2014) BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Reports, 8(5), pp. 1347-1353. (doi: 10.1016/j.celrep.2014.07.057)
2013
Bommert, K.S. et al. (2013) The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Leukemia, 27(2), pp. 441-450. (doi: 10.1038/leu.2012.185)
2012
Liu, L. et al. (2012) Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature, 483(7391), pp. 608-612. (doi: 10.1038/nature10927)
2009
Khanna, A. et al. (2009) MYC-dependent regulation and prognostic role of cip2a in gastric cancer. Journal of the National Cancer Institute, 101(11), pp. 793-805. (doi: 10.1093/jnci/djp103)
2008
Murphy, D.J. , Junttila, M.R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D.A., Brown-Swigart, L., Johnson, L. and Evan, G.I. (2008) Distinct thresholds govern Myc's biological output In vivo. Cancer Cell, 14(6), pp. 447-457. (doi: 10.1016/j.ccr.2008.10.018)
Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J. , Sodir, N.M., Karnezis, A.N., Swigart, L.B., Nasi, S. and Evan, G.I. (2008) Modelling Myc inhibition as a cancer therapy. Nature, 455(7213), pp. 679-683. (doi: 10.1038/nature07260)
Golipour, A., Myers, D., Seagroves, T., Murphy, D. , Evan, G.I., Donoghue, D.J., Moorehead, R.A. and Porter, L.A. (2008) The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis. Cancer Research, 68(10), pp. 3591-3600. (doi: 10.1158/0008-5472.CAN-07-6453)
Rao, M. et al. (2008) Inhibition of cyclin D1 gene transcription by Brg-1. Cell Cycle, 7(5), pp. 647-655. (doi: 10.4161/cc.7.5.5446)
2005
Evan, G.I., Christophorou, M., Lawlor, E.A., Ringshausen, I., Prescott, J., Dansen, T., Finch, A., Martins, C. and Murphy, D. (2005) Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy. Cold Spring Harbor Symposia on Quantitative Biology, 70, pp. 263-273. (doi: 10.1101/sqb.2005.70.054)
2004
Flores, I., Murphy, D.J. , Swigart, L.B., Knies, U. and Evan, G.I. (2004) Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene, 23(35), pp. 5923-5930. (doi: 10.1038/sj.onc.1207796)
Murphy, D.J. , Swigart, L.B., Israel, M.A. and Evan, G.I. (2004) Id2 is dispensable for myc-induced epidermal neoplasia. Molecular and Cellular Biology, 24(5), pp. 2083-2090. (doi: 10.1128/MCB.24.5.2083-2090.2004)
2001
Deeble, P.D., Murphy, D.J. , Parsons, S.J. and Cox, M.E. (2001) Interleukin-6- and cyclic amp-mediated signaling potentiates neuroendocrine differentiation of lncap prostate tumor cells. Molecular and Cellular Biology, 21(24), pp. 8471-8482. (doi: 10.1128/MCB.21.24.8471-8482.2001)
1999
Murphy, D.J. , Hardy, S. and Engel, D.A. (1999) Human SWI-SNF component BRG1 represses transcription of the c-fos gene. Molecular and Cellular Biology, 19(4), pp. 2724-33.
Articles
Vringer, E. et al. (2024) Mitochondrial outer membrane integrity regulates a ubiquitin-dependent and NF-κB-mediated inflammatory response. EMBO Journal, 43(6), pp. 904-930. (doi: 10.1038/s44318-024-00044-1) (PMID:38337057) (PMCID:PMC10943237)
Skalka, G. L., Tsakovska, M. and Murphy, D. (2024) Kinase signaling adaptation supports dysfunctional mitochondria in disease. Frontiers in Molecular Biosciences, 11, 1354682. (doi: 10.3389/fmolb.2024.1354682)
Whyte, D. et al. (2023) NUAK1 governs centrosome replication in pancreatic cancer via MYPT1/PP1β and GSK3β-dependent regulation of PLK4. Molecular Oncology, 17(7), pp. 1212-1227. (doi: 10.1002/1878-0261.13425) (PMID:36975767) (PMCID:PMC10323901)
Farahmand, P. et al. (2023) Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma. Frontiers in Toxicology, 5, 1200650. (doi: 10.3389/ftox.2023.1200650) (PMID:37441092) (PMCID:PMC10333928)
Vitale, I. et al. (2023) Apoptotic cell death in disease—current understanding of the NCCD 2023. Cell Death and Differentiation, 30(5), pp. 1097-1154. (doi: 10.1038/s41418-023-01153-w) (PMID:37100955) (PMCID:PMC10130819)
Villar, V. H. et al. (2023) Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer. Nature Chemical Biology, 19(3), pp. 292-300. (doi: 10.1038/s41589-022-01154-9) (PMID:36280791) (PMCID:PMC9974483)
Yanchus, C. et al. (2022) A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation. Science, 378(6615), pp. 68-78. (doi: 10.1126/science.abj2890) (PMID:36201590) (PMCID:PMC9926876)
Müller, M. et al. (2022) Human-correlated genetic HCC models identify combination therapy for precision medicine [Pre-print]. Research Square, (doi: 10.21203/rs.3.rs-1638504/v1)
Blomme, A. et al. (2022) THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Molecular Medicine, 14(3), e14764. (doi: 10.15252/emmm.202114764) (PMID:35014179) (PMCID:PMC8899912)
Marini, A. et al. (2021) The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nature Communications, 12, 4920. (doi: 10.1038/s41467-021-25173-7) (PMID:34389715) (PMCID:PMC8363647)
Yun, S. et al. (2021) TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discovery, 2(2), pp. 162-185. (doi: 10.1158/2643-3230.bcd-20-0029) (PMID:33860275) (PMCID:PMC8043621)
Rodrigues, F. S., Miranda, V. S., Carneiro-Lobo, T. C., Scalabrini, L. C., Kruspig, B., Levantini, E., Murphy, D. J. and Bassères, D. S. (2020) IKKβ kinase promotes stemness, migration, and invasion in KRAS-driven lung adenocarcinoma cells. International Journal of Molecular Sciences, 21(16), 5806. (doi: 10.3390/ijms21165806) (PMID:32823550) (PMCID:PMC7460870)
Muthalagu, N. et al. (2020) Repression of the type I interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in pancreatic ductal adenocarcinoma. Cancer Discovery, 10(6), pp. 872-887. (doi: 10.1158/2159-8290.CD-19-0620) (PMID:32200350) (PMCID:PMC7611248)
Bott, A. J. et al. (2019) Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism. Cell Reports, 29(5), 1287-1298.e6. (doi: 10.1016/j.celrep.2019.09.056) (PMID:31665640) (PMCID:PMC6886125)
Neidler, S. et al. (2019) Identification of a clinically relevant signature for early progression in KRAS-driven lung adenocarcinoma. Cancers, 11(5), 600. (doi: 10.3390/cancers11050600) (PMID:31032816) (PMCID:PMC6562816)
Scopelliti, A., Bauer, C. , Yu, Y., Zhang, T., Kruspig, B., Murphy, D. J. , Vidal, M., Maddocks, O. D.K. and Cordero, J. B. (2019) A neuronal relay mediates a nutrient responsive gut/fat body axis regulating energy homeostasis in adult Drosophila. Cell Metabolism, 29(2), 269-284.e10. (doi: 10.1016/j.cmet.2018.09.021) (PMID:30344016) (PMCID:PMC6370946)
Muthalagu, N. and Murphy, D. J. (2018) Is oxidative stress MYC’s Achilles heel? Cell Death and Differentiation, 25(7), pp. 1189-1190. (doi: 10.1038/s41418-018-0117-4) (PMID:29844569) (PMCID:PMC6030217)
Kruspig, B. et al. (2018) The ERBB network facilitates KRAS-driven lung tumorigenesis. Science Translational Medicine, 10(446), eaao2565. (doi: 10.1126/scitranslmed.aao2565) (PMID:29925636) (PMCID:PMC6881183)
Port, J. et al. (2018) Colorectal tumors require NUAK1 for protection from oxidative stress. Cancer Discovery, 8(5), pp. 632-647. (doi: 10.1158/2159-8290.CD-17-0533) (PMID:29500295) (PMCID:PMC5935231)
Monteverde, T., Tait-Mulder, J., Hedley, A.,, Knight, J.R., Sansom, O.J. and Murphy, D.J. (2018) Calcium signalling links MYC to NUAK1. Oncogene, 37(8), pp. 982-992. (doi: 10.1038/onc.2017.394) (PMID:29106388)
Blyth, K. G. and Murphy, D. J. (2018) Progress and challenges in Mesothelioma: from bench to bedside. Respiratory Medicine, 134, pp. 31-41. (doi: 10.1016/j.rmed.2017.11.015)
Walton, J. B. et al. (2017) CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Scientific Reports, 7, 16827. (doi: 10.1038/s41598-017-17119-1) (PMID:29203787) (PMCID:PMC5715106)
Farrell, A. S. et al. (2017) MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nature Communications, 8, 1728. (doi: 10.1038/s41467-017-01967-6) (PMID:29170413) (PMCID:PMC5701042)
Port, J. and Murphy, D. J. (2017) Mesothelioma: identical routes to malignancy from asbestos and carbon nanotubes. Current Biology, 27(21), R1173-R1176. (doi: 10.1016/j.cub.2017.07.026) (PMID:29112873)
Murphy, D. J. and Blyth, K. G. (2017) Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'. Cell Death and Differentiation, 24(9), pp. 1473-1474. (doi: 10.1038/cdd.2017.97) (PMID:28622291)
Hock, A. K. et al. (2017) Development of an inducible mouse model of iRFP713 to track recombinase activity and tumour development in vivo. Scientific Reports, 7, 1837. (doi: 10.1038/s41598-017-01741-0) (PMID:28500323) (PMCID:PMC5431786)
Sarosiek, K. A. et al. (2017) Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific sensitivity to cancer therapeutics. Cancer Cell, 31(1), pp. 142-156. (doi: 10.1016/j.ccell.2016.11.011) (PMID:28017613) (PMCID:PMC5363285)
Iltzsche, F. et al. (2017) An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma. Oncogene, 36(1), pp. 110-121. (doi: 10.1038/onc.2016.181) (PMID:27212033)
Bott, A. J. et al. (2015) Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metabolism, 22(6), pp. 1068-1077. (doi: 10.1016/j.cmet.2015.09.025) (PMID:26603296) (PMCID:PMC4670565)
Monteverde, T., Muthalagu, N., Port, J. and Murphy, D. (2015) Evidence of cancer-promoting roles for AMPK and related kinases. FEBS Journal, 282(24), pp. 4658-4671. (doi: 10.1111/febs.13534) (PMID:26426570)
Neidler, S. and Murphy, D. J. (2015) Studying lung cancer progression: insights from genetically engineered mouse models of cancer. Lung Cancer Management, 4(4), pp. 155-157. (doi: 10.2217/lmt.15.18)
Ichim, G. et al. (2015) Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Molecular Cell, 57(5), pp. 860-872. (doi: 10.1016/j.molcel.2015.01.018) (PMID:25702873) (PMCID:PMC4352766)
Leikam, C. et al. (2015) In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells. Cell Death and Disease, 6(4), e1711. (doi: 10.1038/cddis.2015.71) (PMID:25837487)
Murphy, D. J. and Muthalagu, N. (2015) BIM's up first. Molecular and Cellular Oncology, 2(2), e975083. (doi: 10.4161/23723556.2014.975083)
Kamphorst, J. J. and Murphy, D. J. (2014) The 2014 Beatson International Cancer Conference: Powering the Cancer Machine. Cancer and Metabolism, 2(1), 25. (doi: 10.1186/2049-3002-2-25)
Muthalagu, N., Junttila, M. R., Wiese, K. E., Wolf, E., Morton, J. , Bauer, B., Evan, G. I., Eilers, M. and Murphy, D. J. (2014) BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Reports, 8(5), pp. 1347-1353. (doi: 10.1016/j.celrep.2014.07.057)
Bommert, K.S. et al. (2013) The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Leukemia, 27(2), pp. 441-450. (doi: 10.1038/leu.2012.185)
Liu, L. et al. (2012) Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature, 483(7391), pp. 608-612. (doi: 10.1038/nature10927)
Khanna, A. et al. (2009) MYC-dependent regulation and prognostic role of cip2a in gastric cancer. Journal of the National Cancer Institute, 101(11), pp. 793-805. (doi: 10.1093/jnci/djp103)
Murphy, D.J. , Junttila, M.R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D.A., Brown-Swigart, L., Johnson, L. and Evan, G.I. (2008) Distinct thresholds govern Myc's biological output In vivo. Cancer Cell, 14(6), pp. 447-457. (doi: 10.1016/j.ccr.2008.10.018)
Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J. , Sodir, N.M., Karnezis, A.N., Swigart, L.B., Nasi, S. and Evan, G.I. (2008) Modelling Myc inhibition as a cancer therapy. Nature, 455(7213), pp. 679-683. (doi: 10.1038/nature07260)
Golipour, A., Myers, D., Seagroves, T., Murphy, D. , Evan, G.I., Donoghue, D.J., Moorehead, R.A. and Porter, L.A. (2008) The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis. Cancer Research, 68(10), pp. 3591-3600. (doi: 10.1158/0008-5472.CAN-07-6453)
Rao, M. et al. (2008) Inhibition of cyclin D1 gene transcription by Brg-1. Cell Cycle, 7(5), pp. 647-655. (doi: 10.4161/cc.7.5.5446)
Evan, G.I., Christophorou, M., Lawlor, E.A., Ringshausen, I., Prescott, J., Dansen, T., Finch, A., Martins, C. and Murphy, D. (2005) Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy. Cold Spring Harbor Symposia on Quantitative Biology, 70, pp. 263-273. (doi: 10.1101/sqb.2005.70.054)
Flores, I., Murphy, D.J. , Swigart, L.B., Knies, U. and Evan, G.I. (2004) Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene, 23(35), pp. 5923-5930. (doi: 10.1038/sj.onc.1207796)
Murphy, D.J. , Swigart, L.B., Israel, M.A. and Evan, G.I. (2004) Id2 is dispensable for myc-induced epidermal neoplasia. Molecular and Cellular Biology, 24(5), pp. 2083-2090. (doi: 10.1128/MCB.24.5.2083-2090.2004)
Deeble, P.D., Murphy, D.J. , Parsons, S.J. and Cox, M.E. (2001) Interleukin-6- and cyclic amp-mediated signaling potentiates neuroendocrine differentiation of lncap prostate tumor cells. Molecular and Cellular Biology, 21(24), pp. 8471-8482. (doi: 10.1128/MCB.21.24.8471-8482.2001)
Murphy, D.J. , Hardy, S. and Engel, D.A. (1999) Human SWI-SNF component BRG1 represses transcription of the c-fos gene. Molecular and Cellular Biology, 19(4), pp. 2724-33.
Grants
Grants and Awards listed are those received whilst working with the University of Glasgow.
- Dactinomycin has an immunopotentiation effect by inducing MHC-I expression of cancer cells
University of Oxford
2024 - 2025
- National Mouse Genetics Network Business Engagement Fund
Medical Research Council
2024 - 2025
- REMIT: REconstruction of disease evolution in Mesothelioma for Improved Therapy
Cancer Research UK
2023 - 2028
- Differential Expression in Bystander Transcriptomes for Mesothelioma Diagnosis: DEBiT-Meso
British Lung Foundation
2022 - 2025
- Using complex state of the art mouse models of cancer to improve the understanding and treatment of human cancer
Medical Research Council
2022 - 2027
- CRUK Centre Renewal 2021
Cancer Research UK
2022 - 2023
- IAMMED-Meso: Integrated analysis in man and mouse for early detection of Mesothelioma
Cancer Research UK
2022 - 2027
- PREDICT-Meso Collaboration on therapeutic intervention in Mesothelioma (QUB-Wilson)
Queen`s University Belfast
2021 - 2022
- Generation of a unique Glasgow RadNet multimodality molecular imaging dataset measuring dynamic immunometabolic phenotypes during radiotherapy in mouse models of lung cancer
Cancer Research UK
2021 - 2022
- Drug repurposing for mesothelioma prevention: assessment of efficacy in a novel asbestos-accelerated mouse model of human disease
British Lung Foundation
2021 - 2023
- PREDICT-Meso Collaboration on therapeutic intervention in Mesothelioma (Imperial-Pardo)
Imperial College London
2021 - 2021
- PREDICT-Meso: PRE-malignant Drivers Combined with Target-Drug validation in Mesothelioma
Cancer Research UK
2020 - 2025
- Pre-clinical in vivo evaluation of immuno-modulatory therapy in MPM
British Lung Foundation (BLF)
2019 - 2022
- heterotypic intercellular ERBB signalling in early progression of KRAS LuAd
Cancer Research UK
2019 - 2022
- Pre-clinical evaluation of pan-ERBB inhibition to treat KRAS mutant NSCLC
British Lung Foundation
2017 - 2020
- NuSiCC
European Commission
2016 - 2018
- SERPLUC: Suppression of Enzymes Required for Progression of Lung Cancer
European Commission
2013 - 2017
- Metabolic vulnerabilities induced by Myc
Cancer Research UK
2012 - 2013
Research datasets
2019
Scopelliti, A., Bauer, C., Yu, Y., Zhang, T., Kruspig, B., Murphy, D. , Vidal, M., Maddocks, O. and Cordero, J. (2019) A Neuronal Relay Mediates a Nutrient Responsive Gut/Fat Body Axis Regulating Energy Homeostasis in Adult Drosophila. [Data Collection]
2018
Krupig, B., Hedley, A. and Murphy, D. (2018) RNA-seq to investigate impact of treatment of KRAS mutant A549 lung adenocarcinoma cells with the multi-ERBB inhibitor Neratinib. [Data Collection]
Krupig, B., Hedley, A. and Murphy, D. (2018) RNA-seq to investigate impact of treatment of KRAS mutant NCI-H2009 lung adenocarcinoma cells with the multi-ERBB inhibitor Neratinib. [Data Collection]
Krupig, B., Hedley, A. and Murphy, D. (2018) RNA-seq to investigate impact of treatment of KRAS mutant NCI-H358 lung adenocarcinoma cells with the multi-ERBB inhibitor Neratinib. [Data Collection]
Neidler, S., Hedley, A. and Murphy, D. (2018) Progression of KRas^G12D;Rosa26-MYC tumours to invasive disease. [Data Collection]
Monteverde, T., Neilson, L., Zanivan, S. R. and Murphy, D. (2018) Colorectal tumors require NUAK1 for protection from oxidative stress. [Data Collection]
Port, J., Hedley, A. and Murphy, D. (2018) E-MTAB-6265 - Transcription profiling by RNA-seq of murine colon tumours after in situ depletion of Nuak1. [Data Collection]
Port, J., Muthalagu, N., Hedley, A. and Murphy, D. (2018) Comparison of the transcriptomic impact of NRF2 depletion with that of NUAK1 depletion in SW480 colorectal cancer cells. [Data Collection]
Muthalagu, N., Kalna, G., Hedley, A. and Murphy, D. (2018) RNA-SEQ analysis of human U2OS cells with/without depletion of NUAK1 by shRNA. [Data Collection]
